Roussel Uclaf controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile2 entries
1997
Withdrawal of Roussel Uclaf’s direct mifepristone business
After Hoechst acquired the remaining shares, it announced the end of Roussel Uclaf’s manufacture and sale of Mifegyne and transferred non-U.S. medical-use rights to Exelgyn. The decision continued the long-running debate over corporate control and access to abortion medicines.
1988
Mifepristone distribution controversy
After anti-abortion protests and pressure associated with majority shareholder Hoechst AG, Roussel Uclaf’s board voted to stop distributing mifepristone shortly after French approval. The French government ordered distribution to resume, arguing that access to an approved medical product could not be withdrawn because of the abortion controversy.